These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 267283)

  • 1. [Characteristics of the morphology and function of the thrombocytes in myeloproliferative diseases].
    Petrov MN; Vashkinel' VK
    Probl Gematol Pereliv Krovi; 1977 May; 22(5):18-23. PubMed ID: 267283
    [No Abstract]   [Full Text] [Related]  

  • 2. Platelet aggregation and platelet factor 3 activity in myeloproliferative disorders.
    Tangün Y
    Thromb Diath Haemorrh; 1971 Jun; 25(2):241-51. PubMed ID: 5284903
    [No Abstract]   [Full Text] [Related]  

  • 3. Platelet survival, platelet factor-4 and bleeding time in myeloproliferative disorders.
    Berild D; Hasselbalch H; Knudsen JB
    Scand J Clin Lab Invest; 1987 Sep; 47(5):497-501. PubMed ID: 3477851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Glycosaminoglycans of human thrombocytes in normal conditions, in chronic myeloid leukosis, myelofibrosis and polycythemia vera].
    Kharchenko MF
    Vopr Med Khim; 1973; 19(6):613-7. PubMed ID: 4277844
    [No Abstract]   [Full Text] [Related]  

  • 5. Spontaneous platelet aggregation in myeloproliferative disorders. A preliminary study.
    Barbui T; Battista R; Dini E
    Acta Haematol; 1973; 50(1):25-9. PubMed ID: 4200801
    [No Abstract]   [Full Text] [Related]  

  • 6. Platelet function and arachidonate metabolism in patients with myeloproliferative disorders.
    Okuma M
    Nihon Ketsueki Gakkai Zasshi; 1980 Dec; 43(6):1139-44. PubMed ID: 6800179
    [No Abstract]   [Full Text] [Related]  

  • 7. Platelet defects in the myeloproliferative disorders.
    Inceman S; Tangün Y
    Ann N Y Acad Sci; 1972 Oct; 201():251-61. PubMed ID: 4509685
    [No Abstract]   [Full Text] [Related]  

  • 8. Platelet and fibrinogen kinetics in the chronic myeloproliferative disorders.
    Brodsky I; Kahn SB; Ross EM; Petkov G
    Cancer; 1972 Dec; 30(6):1444-50. PubMed ID: 4509103
    [No Abstract]   [Full Text] [Related]  

  • 9. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
    Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
    Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma fibronectin in idiopathic myelofibrosis and related chronic myeloproliferative disorders.
    Hasselbalch H; Clemmensen I
    Scand J Clin Lab Invest; 1987 Sep; 47(5):429-33. PubMed ID: 3477850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The role and participation of thrombocytes in hemostasis in the myeloproliferative syndrome].
    Zaĭtseva VN
    Vrach Delo; 1971 Jan; (1):72-6. PubMed ID: 5280699
    [No Abstract]   [Full Text] [Related]  

  • 12. Hypocholesterolemia in myeloproliferative disorders.
    Spanos GA; Bajaj K; Rosner F
    Arch Intern Med; 1981 Jan; 141(1):137-8. PubMed ID: 6934710
    [No Abstract]   [Full Text] [Related]  

  • 13. [Hemostasis disorders with reduced activity of the von Willebrand factor in myeloproliferative syndromes].
    Leupin L; Beck EA; Furlan M; Bucher U
    Schweiz Med Wochenschr; 1983 May; 113(19):713-6. PubMed ID: 6603016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Template bleeding time and clinical hemorrhage in myeloproliferative disease.
    Murphy S; Davis JL; Walsh PN; Gardner FH
    Arch Intern Med; 1978 Aug; 138(8):1251-3. PubMed ID: 277084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Megakaryocytopoiesis in myeloproliferative disorders].
    Podolak-Dawidziak M
    Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
    [No Abstract]   [Full Text] [Related]  

  • 16. [Granulocyte clearance and granulocyte kinetics in myeloproliferative syndromes].
    Jungi WF; Meuret G; Senn HJ
    Schweiz Med Wochenschr; 1974 Jan; 104(4):133-5. PubMed ID: 4521299
    [No Abstract]   [Full Text] [Related]  

  • 17. The peripheral blood in polycythaemia vera and myelofibrosis.
    Leblond PF; Weed RI
    Clin Haematol; 1975 Jun; 4(2):353-71. PubMed ID: 1102192
    [No Abstract]   [Full Text] [Related]  

  • 18. Presence of a myeloproliferative factor in patients with polycythemia vera and agnogenic myeloid metaplasia. I. Expansion of the erythropoietin-responsive stem cell compartment.
    Ward HP; Vautrin R; Kurnick J; Robinson WA
    Proc Soc Exp Biol Med; 1974 Oct; 147(1):305-8. PubMed ID: 4531056
    [No Abstract]   [Full Text] [Related]  

  • 19. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function.
    Barbui T; Cortelazzo S; Viero P; Bassan R; Dini E; Semeraro N
    Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1593-9. PubMed ID: 6580171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnostic considerations in myelofibrosis].
    Dieska D; Gocárová K; Horváth A; Vahancík A
    Bratisl Lek Listy; 1970 Nov; 54(5):637-42. PubMed ID: 5276096
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.